RxDoctor Payments Data

Eleanor Vierra

Acute Care · Sacramento, CANPI 1487726550

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $51,605 of the $63,844 with a category attached, or 80.8%. Johnson & Johnson accounts for 96.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $24,680 and has fallen 99.2% since, to $202 in 2025. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$63,844in general payments, 2019–2025

Across 83 payments — averaging $769.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$62K
  • Biotronik Inc.$746
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$349
  • Boston Scientific$291
  • Abbott$269
  • Medtronic$170
  • plus $401 from 5 others

What the payments were for

  • Speaking & faculty fees$51,60581%
  • Travel & lodging$9,44715%
  • Food & beverage$2,7924%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,844 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$90,907
Medicare patients
383
Services billed
1,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$75,378
EntrestoSacubitril/Valsartan52$59,855
MultaqDronedarone Hcl29$40,438
XareltoRivaroxaban30$35,554
JardianceEmpagliflozin14$9,460
Digoxin32$3,775
Amiodarone Hcl97$1,330
Sotalol AfSotalol Hcl29$1,221
Metoprolol Succinate61$1,217
Flecainide Acetate43$1,159
SotalolSotalol Hcl40$850
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$648
Valsartan18$564
Spironolactone47$373
Bumetanide12$294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$61,618$35,55430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,153 acute care providers in California.

Other acute care in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →